Climb Bio (CLYM)

• Market cap: $116M
• 1 day: -1.73%
• 5 days: -10.53%
• 1 month: -24.78%
• 3 months: -22.37%
• 6 months: 40.5%
• Year to date: -17.87%
• 1 year: -43.33%
• 5 years: -89.31%
• 10 years: -89.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18